Cigna (CI) Stock Forecast & Price Target

Cigna Group is well-positioned in the healthcare industry due to its strong pharmacy benefit management and health insurance services, particularly through its recent merger with Express Scripts. The company has secured major contracts with top-tier insurers and the Department of Defense, and its focus on self-funding arrangements with employers has led to strong financial performance with 16 million US and 2 million international medical members covered as of December 2025. Despite some risks, including managing healthcare costs and potential client losses, Cigna's emphasis on diversification, including through its specialty drug capabilities, and its commitment to sustainability and diversity in leadership positions, make it a solid long-term investment.

Cigna Group is facing challenges in its healthcare business due to soft MLRs, exiting the exchange market, and the strategic review of EviCore. Additionally, the company's PBM and specialty pharmacy services are experiencing margin pressure and a decline in scripts due to membership loss. These factors, combined with the economic impact of the exit from the exchange market, may result in lower-than-expected financial performance in 2027. However, Cigna's efforts to improve access, cost, and quality of care may appeal to sustainability-oriented investors. The recent rollout of an AI risk prediction model has shown promising results, but it remains to be seen if it can effectively reduce healthcare costs in the long term.